Skip to main content
SJRES 22 110th Congress Senate Health Administrative procedure Blood Cancer Congress Congressional veto Department of Health and Human Services Government Operations and Politics Law Medicare Social Welfare

A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services within the Department…

Show full title

A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services within the Department of Health and Human Services relating to Medicare coverage for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions.

Introduced: October 22, 2007 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 110th Congress ended
It never became law before the 110th Congress (2007–2008) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 22, 2007
Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S13201-13202)
Oct 22, 2007
Sponsor introductory remarks on measure. (CR S13200-13201)
Oct 22, 2007
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Disapproves a specified rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to Medicare coverage for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions.

Declares that such rule shall have no force or effect.

What's happening now October 22, 2007

Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S13201-13202)

 Related & companion bills 1
  • HJRES 54 Identical bill Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Ce…
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 7
All 7 Democratic 4 Republican 3
D
Murray, Patty
Washington · Dec 5, 2007
 D
Durbin, Richard J.
Illinois · Dec 3, 2007
 R
Graham, Lindsey
South Carolina · Nov 15, 2007
 R
Collins, Susan M.
Maine · Oct 26, 2007
 D
Cantwell, Maria
Washington · Oct 22, 2007
 R
Crapo, Mike
Idaho · Oct 22, 2007
 D
Wyden, Ron
Oregon · Oct 22, 2007
Cite this page click to expand
APA
U.S. Congress. (2026). S.J. Res. 22: A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services within the Department of Health and Human Services relating to Medicare coverage for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions.. 110th Congress. Open America. https://openamerica.io/bill/110-SJRES-22/
MLA
"S.J. Res. 22: A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services within the Department of Health and Human Services relating to Medicare coverage for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions.." 110th Congress, 2026, Open America, https://openamerica.io/bill/110-SJRES-22/.
Bluebook (legal)
S.J. Res. 22, 110th Cong. (2026), https://openamerica.io/bill/110-SJRES-22/.
Markdown link
[S.J. Res. 22: A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services within the Department of Health and Human Services relating to Medicare coverage for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions.](https://openamerica.io/bill/110-SJRES-22/)
Report a problem